Tirosint - Sol
Subpotent Drug
948 recalls · Class II, newest first
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Failed Dissolution Specification: Out of specification dissolution results at time point zero. The OOS was above specified values.
CGMP Deviations: FDA analysis found product to contain acetaldehyde and acetal above specification limits.
CGMP Deviations: FDA analysis found product to contain acetaldehyde and acetal above specification limits.
CGMP Deviations: Voluntary recall of all hand sanitizer distributed after March 31, 2022, due to FDA issued guidance to cease placing hand sanitizer product, produced under temporary approval, into the market after March 31, 2022.
CGMP Deviations: Voluntary recall of all hand sanitizer distributed after March 31, 2022, due to FDA issued guidance to cease placing hand sanitizer product, produced under temporary approval, into the market after March 31, 2022.
Presence of Foreign Substance: manufacturer recalled this re-packaged product due to reports of a small piece of green plastic embedded in the crack towards the edge of the tablet.
Failed Impurity (Deacetyl Diltiazem Hydrochloride) specification during stability testing and failed dissolution testing at FDA laboratory.
Short Fill
CGMP Deviations: potential for trace amounts of product carryover.
CGMP Deviations: potential for trace amounts of product carryover.
Presence of Foreign Substance: Presence of a small piece of green plastic embedded in the crack towards the edge of the tablet.
Failed Dissolution Specifications: This recall is being initiated in support of the recall by the manufacturer which included lots that were packaged for BluePoint Laboratories.
CGMP Deviations: initiated due to violations of CGMP manufacturing practices
CGMP Deviations: initiated due to violations of CGMP manufacturing practices
Lack of Assurance of Sterility
Failed Dissolution Specification
Failed Dissolution Specification
Failed Dissolution Specification